로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > LIGHT

LIGHT

요약

Name:Tumor necrosis factor superfamily member 14
Target Synonym:CD258 Antigen,Herpes Virus Entry Mediator Ligand,TNFSF14,Herpesvirus Entry Mediator Ligand,LIGHT,Tumor Necrosis Factor (Ligand) Superfamily, Member 14,CD258,HVEM-L,Tumor Necrosis Factor Ligand 1D,LTg,HVEML,TNF Superfamily Member 14,Tumor Necrosis Factor Ligand Superfamily Member 14,Tumor Necrosis Factor Superfamily Member 14
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

제품 리스트 비교 또는 구매

일부의 생물활성 데이터

LIT-H5269-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human LIGHT, Fc Tag (active trimer) (MALS verified) (Cat. No. LIT-H5269) induced cytotoxicity in HT-29 cells. The ED50 for this effect is 1.29-2.38 ng/mL (Routinely tested).

LIT-H5242-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human LIGHT, His Tag (active trimer) (MALS verified) (Cat. No. LIT-H5242) induced cytotoxicity in HT-29 cells. The ED50 for this effect is 1.11-3.87 ng/mL (Routinely tested).

LIT-H5256-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human DcR3, Fc Tag (Cat. No. TNB-H5255) on AHC Biosensor, can bind Human LIGHT, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. LIT-H5256) with an affinity constant of 1.64 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

LIT-H5242-ELISA
Human LIGHT, His Tag (active trimer) (MALS verified)Human LIGHT, His Tag (active trimer) (MALS verified) (Cat. No. LIT-H5242) ELISA bioactivity

Immobilized Human HVEM, Fc Tag (Cat. No. HVM-H5258) at 5 μg/mL (100 μL/well) can bind Human LIGHT, His Tag (active trimer) (MALS verified) (Cat. No. LIT-H5242) with a linear range of 16-63 ng/mL (QC tested).

사용자 리뷰

Synonym Name

CD258 antigen,CD258,HVEM-L,LIGHT,LTg,TNFSF14,TR2,HVEML

Background

Tumor necrosis factor ligand superfamily member 14(LIGHT) is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Quisovalimab CERC-002; AEVI-002; MDGN-002; SAR-252067; AVTX-002 La Jolla Pharmaceutical Company, Kyowa Hakko Kirin Details
CBS-001 CBS-001 Phase 1 Clinical Centessa Pharmaceuticals Plc Idiopathic Pulmonary Fibrosis; Inflammation Details

This web search service is supported by Google Inc.

totop